AI Spending and Soft Pharma Demand Weigh on Doximity After Weak Fiscal 2027 Outlook

Doximity stock sinks as guidance disappoints despite strong user engagement

Doximity (DOCS) fell sharply after reporting fiscal fourth-quarter results that showed slowing revenue growth and weaker-than-expected guidance for fiscal 2027.

While the company continued to grow physician engagement and expand adoption of its AI tools, investors focused on softer outlooks for revenue and profitability as the company increases spending on AI infrastructure and faces a cautious healthcare advertising market.

Key Points

• Doximity (DOCS) forecast fiscal 2027 revenue of $664 million to $676 million, below analyst expectations of roughly $697 million.
• Fiscal fourth-quarter adjusted earnings came in at 26 cents per share, missing Wall Street estimates.
• Nearly half of Doximity’s prescribers used AI tools during the quarter as the company expanded its clinical AI offerings.

What drove the sharp selloff in DOCS stock?

Doximity reported fiscal fourth-quarter revenue of $145.4 million, up 5% year over year and slightly ahead of analyst expectations.

However, adjusted earnings of 26 cents per share fell short of Wall Street forecasts of 28 cents per share and declined from 36 cents a year earlier.

The larger concern for investors came from the company’s forward guidance.

Doximity projected fiscal 2027 revenue between $664 million and $676 million, well below analyst expectations near $697 million. The outlook implies annual growth of roughly 3% to 5%, a significant slowdown from prior periods.

The company also guided first-quarter fiscal 2027 revenue below expectations, forecasting sales between $151 million and $152 million versus Wall Street estimates around $154 million.

Shares dropped sharply as investors reacted to slowing growth, softer digital pharmaceutical advertising demand, and margin pressure tied to increased AI-related spending.

Why are AI investments pressuring margins?

Management said the company is increasing investments in AI infrastructure, engineering hires, peer-review tools, and brand marketing as it expands its artificial intelligence offerings.

Those investments weighed on profitability during the quarter.

Adjusted EBITDA declined to $65.8 million from $69.7 million a year earlier, while adjusted EBITDA margin fell to 45.3% from 50.4%.

Gross margin also slipped to 89% from 91% as AI compute costs increased.

Executives acknowledged that monetization of AI products remains in its early stages while infrastructure costs are already impacting margins.

Still, Doximity highlighted growing engagement with its AI platform.

The company reported more than 800,000 active prescribers during the quarter, with nearly half using clinical AI tools. Management also said AI search and transcription users tripled over the last nine months.

Doximity further announced an integration partnership with Aledade that will bring components of its clinical AI suite into Aledade’s healthcare systems.

What matters next for Doximity?

Investors will likely watch whether Doximity can stabilize growth while turning rising AI engagement into stronger revenue generation.

Executives said the healthcare professional advertising market remains soft amid broader macroeconomic uncertainty and changing pharmaceutical marketing behavior.

Management noted that some pharmaceutical companies are shortening advertising commitments and seeking lower-cost AI-driven marketing solutions.

Analysts also pointed to concerns that Doximity’s AI Search product missed the key upfront selling season, potentially delaying meaningful revenue contribution until later in fiscal 2027.

Despite the weak market reaction, several operational metrics remained solid.

Trailing twelve-month net revenue retention was 109%, while the company’s top 20 customers posted 114% retention. Customers generating at least $500,000 in annual subscription revenue increased to 125 from 118 a year earlier.

Free cash flow also remained a bright spot, reaching a quarterly record of $107 million and $317 million for the full fiscal year.

What It Means for Investors

Doximity’s earnings reaction reflected growing investor sensitivity to slowing software growth and AI-related margin pressure in today’s stock market news environment.

While the company continues to expand physician engagement and adoption of its AI products, weaker guidance and slowing pharmaceutical advertising demand weighed heavily on market sentiment.

For investors following DOCS stock news and broader market news today tied to healthcare technology and AI software adoption, the key issue remains whether Doximity can convert growing platform engagement into faster revenue growth while protecting profitability.

Conclusion

Doximity (DOCS) delivered another quarter of strong physician engagement and growing AI adoption, but weaker-than-expected fiscal 2027 guidance overshadowed those gains.

The company is investing aggressively in AI-powered healthcare tools at a time when pharmaceutical advertising demand remains uncertain, creating pressure on margins and near-term growth expectations. Investors now appear focused on whether Doximity can balance long-term AI expansion with improving financial performance over the coming quarters.

FAQs

Why did Doximity stock fall?

Doximity stock fell after the company issued fiscal 2027 revenue guidance that came in below Wall Street expectations.

What were Doximity’s quarterly earnings results?

Doximity reported adjusted earnings of 26 cents per share on revenue of $145.4 million.

How many prescribers use Doximity’s platform?

Doximity reported more than 800,000 active prescribers during the quarter.

How is Doximity using AI?

The company is expanding clinical AI tools, including AI search, transcription services, and workflow assistants for healthcare professionals.

What pressured Doximity’s margins?

Margins were pressured by rising AI infrastructure costs, engineering investments, and broader spending tied to AI product development.

This article was created with AI assistance and reviewed by an editor. For details, please refer to our Terms of Use.

Explore Research with Stock Investor

For readers evaluating long-term market opportunities, Stock Investor is SharperTrades’ investing platform built around portfolio management, market research, and AI-assisted analysis. Members receive research reports, portfolio updates, conviction tracking, and educational insights designed to support disciplined investing decisions.

Follow the Market with SharperTrades

SharperTrades offers additional ways to stay connected to the market. Block Orders tracks institutional activity and highlights active trade setups and price behavior across long and short opportunities. For options-focused traders, Essential Option Income provides a structured approach to income strategies.

Learn More with SharperTrades Academy

If you value the clear, explanatory approach of Market Brief, explore SharperTrades Academy, where we publish in-depth content and structured programs covering technical analysis, options, and risk management to help you better interpret market behavior.

Track Market Participation with DarkOption Flow

For deeper insight into how markets behave during major events, DarkOption Flow provides tools designed to monitor market participation and activity. It can be used alongside price action and sentiment analysis, particularly during periods of elevated volatility.

Risk Disclosure

All content is provided for educational purposes only and does not constitute investment advice. Trading involves risk, and past performance is not indicative of future results. Please review our full Risk Disclosure for additional information.